Audit: QRS - Phosphatidylcholine for Health & Longevity

Audit conducted on 11/06/2026 21:55 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	97
Passed	87
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Lede, Protocol, Time to effect, gates, tiers, Monitoring and Qualitative items all trace to ER text (Conclusion, Therapeutic Protocol, Practical Considerations, Key Interactions & Contraindications, Monitoring table).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious wording kept: “unconfirmed for supplements” (ER “unconfirmed for supplemental PC”), “no controlled trials exist”, “separately taken PC untested”, “No established target”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No claim strengthened or softened; contraindication scopes (“medicinal-dose essential phospholipids”, “at supplemental doses”) kept as in ER.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from “Populations who should avoid”; interactions from the Documented/Theoretical lists; no modifying factor relabeled.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, expert names, NCT IDs or brand names in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is expert, accessible, objective, and data-driven	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Protocol and Monitoring items are stated descriptively (“used only to close gaps”, “argues for stopping”), as in the ER.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses the reader directly — it presents evidence, not guidance	🟢	No “you”/”your” or imperatives addressed to the reader.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Lede plain; remaining technical terms are ER labels or ER consequence wording carried verbatim.
2.8	Information is presented in a concise and very compact manner	🟢
2.9	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.10	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.11	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.13	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No “anti-aging” wording.
2.14	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Formal terms used (“capsules”, “intravenous”, “injected PC”, “adverse”); no lay route-of-administration phrasing.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” Gate headings: “Contraindications”, “Key Interactions” Tier labels: “High”, “Medium”, “Low”, “Speculative” Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and column headers match the template (lines 446, 483, 525, 545, 557, 588, 607, 611-613, 693).
3.2	Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name	🟢	All template data-qrs-var names present; marker_# and qualitative_item_# expanded per 14.2/15.2.
3.3	Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well	🟢	Diff against template shows changes only inside data-qrs-var spans, plus style=”display:none” on empty tier spans (required by 12.5/13.5).

4. Formatting

#	Description	Result	Comments
4.1	An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over.	🟢	Empty tiers (Benefits High; Risks High, Medium) hidden; no empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Interaction and Protocol labels are ER bold labels verbatim (glosses/extra examples trimmed only).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Example lists trimmed (tacrine, amitriptyline dropped) with remaining words unshortened; no paraphrased labels.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit.	🟢	No trailing dash clauses, glosses, untrimmed example lists or repetitions found.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment is line 2, directly after <!doctype html>.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Values trimmed; only duration “00:01” quoted (contains a colon).
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.10.25 matches QRS.md version.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	2026-1106-2127
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name	🟢	Opus
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model	🟢	Opus 5.5
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 21: “Phosphatidylcholine for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	11/06/2026 from 2026-1106-2127.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “Phosphatidylcholine, the main cell-membrane fat and chief food form of choline, is a supplement promoted for liver health and memory.”
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the Conclusion: narrow liver-fat/blood-sugar finding, manufacturer funding, failed claims, unconfirmed heart signal, mild side effects.
7.3	[at_a_glance] is no longer than 70 words	🟢	70 words (script count).
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each fact maps to Motivation/Conclusion and the Low-tier cardiovascular “Net” sentence.
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “long-term blood sugar” used for HbA1c.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Only “one manufacturer-funded trial”; no names, years or sizes.
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER “Populations who should avoid” entries present (lines 548-552).
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Attributions (“label contraindication”, KDIGO) and the trailing “— inferred from reduced TMAO clearance” clause stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Scopes and staging kept: “(soybean-derived products)”, “(medicinal-dose essential phospholipids)”, “(stage G4–G5, eGFR below 30 mL/min/1.73 m²)”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation in contraindications.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section is populated; ER lists five populations.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found	🟢	Five documented interactions listed; Alcohol (“no protective interaction found”) correctly excluded.
9.3	[caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label	🟢	All four theoretical interactions listed (lines 574-577).
9.4	The ER placeholder “None identified” is never an item: it means that group is empty	🟢
9.5	Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause	🟢	No item carries “(theoretical)”, “inferred from” or a mechanism clause.
9.6	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Items reduced to ER Consequence text; mitigations and study details stripped.
9.7	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists kept (trimmed to at least one example each).
9.8	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation in interactions.
9.9	If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER theoretical group is not empty.
9.10	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section is populated.
9.11	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g.	N/A	Section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Therapeutic Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from that section	🟢	Liver-support regimen, food-first choline approach and IV phospholipid exchange; the investigational colitis regimen (failed phase III, not central to longevity) reasonably omitted.
10.3	If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	N/A	ER names more than three actionable aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Liver fat (3 months), HbA1c (6 months), choline status (within weeks) from Practical Considerations, Expected Benefits and Discontinuation.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered by primary liver-fat endpoint, then HbA1c (both Medium), then choline status (Low).
11.3	If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	N/A	ER provides three time-to-effect aspects.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items reduced to ER benefit headings; no effect sizes or qualifiers.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content.
12.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high hidden with style=”display:none” (line 527).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items reduced to ER risk headings (“via TMAO” trimmed); no frequencies.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high and risks_medium hidden with style=”display:none” (lines 590, 593).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢
14.2	All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names	🟢	All six ER biomarkers (ALT, CAP, HbA1c, TMAO, eGFR, INR) listed as marker_1 to marker_6.
14.3	[marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER”	🟢	Targets match ER table; ER “No established target” wording carried where the ER gives it.
14.4	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty.	🟢	Cadence mirrors the ER Monitoring paragraph.
14.5	If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template	N/A	ER names measurable biomarkers.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢
15.2	All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 …	🟢	All five ER qualitative markers listed as qualitative_item_1 to _5.
15.3	If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template	N/A	ER names qualitative markers.

Issues 11/06/2026 21:55

Pass rate 100.00%. No issues found.

Issues 11/06/2026 21:49

1. 4.5 / 9.7 — Untrimmed interaction example lists: “Cholinesterase inhibitors (tacrine, donepezil, rivastigmine)” at line 564 and “Anticholinergic drugs (oxybutynin, diphenhydramine, amitriptyline)” at line 575 carry all three ER examples although the sheet runs past one A4 page.

Fixes 11/06/2026 21:49

1. 4.5 / 9.7 — Trimmed interaction example lists: Shortened “(tacrine, donepezil, rivastigmine)” to “(donepezil, rivastigmine)” and “(oxybutynin, diphenhydramine, amitriptyline)” to “(oxybutynin, diphenhydramine)”, keeping the ER’s own example names.

Issues 11/06/2026 21:45

1. 4.5 — Optional glosses in qualitative items: Qualitative items 2 and 4 (lines 699, 705) keep appositive glosses “, as an early sign of excess trimethylamine” and “, the label’s liver-complaint symptoms”, which are cut to fit the one-page budget.

Fixes 11/06/2026 21:45

1. 4.5 — Optional glosses removed: Shortened qualitative_item_2 to “Body or breath odor” and qualitative_item_4 to “Upper-abdominal discomfort or pressure”, dropping the appositive glosses.

Issues 11/06/2026 21:43

1. 2.14 — Lay “cell-wall” wording: The lede at line 439 calls PC “the main cell-wall fat”; human cells have membranes, not walls, and the ER Conclusion uses “the body’s main membrane fat”.

Fixes 11/06/2026 21:43

1. 2.14 — Lay “cell-wall” wording: Changed “the main cell-wall fat” to “the main cell-membrane fat” in the lede (word count unchanged at 70).

Issues 11/06/2026 21:37

1. 7.2 — Main concern missing from lede: The at_a_glance text at line 439 omits the ER Conclusion’s “main concern” (the dietary choline/TMAO link to heart disease or death, not seen with phosphatidylcholine supplements), which a risk-aware reader needs.

Fixes 11/06/2026 21:37

1. 7.2 — Main concern added to lede: Rewrote the at_a_glance text (kept at 70 words) to add “A suspected heart risk from dietary choline is unconfirmed for supplements”, condensing the opening clause to make room.

Issues 11/06/2026 21:33

1. 2.7 — MASLD acronym and jargon: marker_2_why (line 636) “Primary endpoint in the MASLD trial” and marker_3_why (line 647) “Fell in the MASLD trial” use the unexpanded acronym MASLD and the research term “primary endpoint” instead of plain wording.
2. 4.5 — Optional gloss and repetition: The CKD contraindication (line 552) keeps the unused abbreviation gloss “(CKD)”, and time_1_sub (line 495) “Significant at 3 months and sustained at 6 months” repeats the “3 months” already given in time_1_value.

Fixes 11/06/2026 21:33

1. 2.7 — MASLD acronym and jargon: Changed marker_2_why from “Primary endpoint in the MASLD trial” to “Main outcome in the fatty liver trial” and marker_3_why from “Fell in the MASLD trial” to “Fell in the fatty liver trial”.
2. 4.5 — Optional gloss and repetition: Removed the unused “(CKD)” gloss from the kidney-disease contraindication and shortened time_1_sub to “Sustained at 6 months”.

Issues 11/06/2026 21:30

1. 13.3 — Mechanistic hint in risk: The Low risk item at line 597 reads “Cardiovascular disease and mortality via TMAO”; “via TMAO” is a mechanistic hint that the tier rule strips.

Fixes 11/06/2026 21:30

1. 13.3 — Mechanistic hint removed: Changed the Low risk item “Cardiovascular disease and mortality via TMAO” to “Cardiovascular disease and mortality”.